This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation...
Date First Received: May 19, 2006
Last Updated: May 22, 2006
Verified by: Robin, Alan L., M.D., May 2006
Clinical Trial Phase: Phase 4 | Start Date: December 2005
Overall Status: Completed
Estimated Enrollment: 60
Brief Summary
Official Title: “An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures”
Condition Keyword(s):
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacodynamics Study
Detailed Clinical Trial Description
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Intervention(s) in this Clinical Trial
- Drug: travoprost, latanoprost, or bimatoprost
- Drug: Additional ocular hypotensive medication
Outcome Measures for this Clinical Trial
Primary Measures
- Compliance.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Currently using one or two topical ocular hypotensive medications
Exclusion Criteria:
- Hypersensitivity to any component of medication
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Robin, Alan L., M.D.
Overall Clinical Trial Officials and Contacts
Alan L. Robin, MD Principal Investigator Alan L. Robin, M.D.
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00329095
Study ID Number: GMED-01
ClinicalTrials.gov Identifier: NCT00329095
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
